![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Active Filter(s):
Details:
Adults with heart failure who took canagliflozin, a medication originally developed to treat type 2 diabetes, reported improvements in their heart failure symptoms whether or not they also had type 2 diabetes.
Lead Product(s): Canagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JNJ-28431754
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Scientific Affairs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2021